Praesidian doubles up with pharma deal
The mezzanine firm’s second investment in Meta Pharmaceutical Services brings its exposure to $14m.
The mezzanine firm’s second investment in Meta Pharmaceutical Services brings its exposure to $14m.
Copyright PEI Media
Not for publication, email or dissemination